Terlipressin narrowly cleared an FDA advisory committee in mid-2020 for HRS, after the agency questioned the data in Mallinckrodt's phase 3 CONFIRM trial in HRS, suggesting it would like to see ...

Mallinckrodt acquired terlipressin via the $2.3-billion purchase of Ikaria in 2015, inheriting a programme that was first submitted to the FDA in 2009 and rejected a few months later with a ...

特利加压素，以Terlivaz等品牌销售，是一种血管加压素的类似物，用作治疗低血压的血管活性药物。当去甲肾上腺素无效时，它被发现是有效的。特利加压素是一种血管加压素受体激动剂。 特利加压素于 2022 年在美国获批用于医疗用途。美国食品药品管理局 (FDA) 将其视为同类首创药物。

Hepatorenal syndrome-acute kidney injury reversal and liver transplant rates in patients treated with terlipressin. Abstract to be presented at the American Society of Nephrology (ASN ...

The patent covers a liquid formulation of terlipressin acetate that remains stable at room temperature for up to 24 months, which is a significant improvement over the currently available ...

Acute kidney injury is being redefined as a collection of syndromes, each of which could be targeted by specific biomarkers.

Patents covering BioVie’s terlipressin liquid formulation now secured in the United States, India, Japan and Chile, and are pending in eight additional markets Liquid formulation has ...

Favorable capital market conditions last week enabled the company to raise over $15 million from secondary offerings, and the proceeds allow the Company to fund fully the costs of this upcoming ...

New research challenges the traditional practice of continuing vasoconstrictor therapy for 5 days after endoscopic variceal ...

The exclusive event, hosted by RedChip Companies, will feature Cuong Do, President and CEO of BioVie, who will share insights and developments on the Co Patents covering BioVie’s terlipressin ...

– Pooled analysis from Phase 3 clinical trials highlights liver transplant rates in adult patients with HRS with rapid reduction in kidney function treated with TERLIVAZ 1 – The rate of HRS ...